Systolic Hypertension

Continuing Education Activity

Isolated systolic hypertension is the predominant form of hypertension in the elderly population. Traditionally it has been defined as a systolic blood pressure (SBP) above 140 mmHg with a diastolic blood pressure (DBP) of less than 90 mmHg. It is estimated that 15 percent of people 60 years old and above have isolated systolic hypertension. Per the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline, however, an SBP of 130 mm Hg is now considered hypertensive at all ages. The new definition of hypertension will lead to an increased number of elderly being diagnosed with high blood pressure. Isolated systolic hypertension remains an important public health concern as chronically untreated high SBP patients carry significant mortality and morbidity.


  • Describe the factors that contribute to systolic hypertension.
  • Review the diagnosis of systolic hypertension
  • Explain management strategies for hypertension.
  • Summarize the importance of collaboration and coordination amongst the interprofessional team in optimizing the care of patients with systolic hypertension.


Isolated systolic hypertension is the predominant form of hypertension in the elderly population[1]. Traditionally defined as systolic blood pressure (SBP) above 140 mm Hg with diastolic blood pressure (DBP) of less than 90 mm Hg, it is estimated that 15% of people aged 60 years and above have isolated systolic hypertension. Per the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline, however, an SBP of 130 mm Hg is now considered hypertensive at all ages[2]. The new definition of hypertension will lead to an increased number of elderly being diagnosed with high blood pressure. Isolated systolic hypertension remains an important public health concern as chronically untreated high SBP patients carry significant mortality and morbidity. 


Most patients with hypertension have primary hypertension, which is also known as essential hypertension. Rarely, isolated systolic hypertension is attributed to other causes of secondary hypertension such as hypothyroidism/hyperthyroidism, chronic kidney disease, peripheral vascular disease, diabetes mellitus, aortic insufficiency, arteriovenous fistula, anemia, Paget disease, and atherosclerotic renal artery stenosis[3].


Isolated systolic hypertension is common in the elderly population. Based on data from the National Health and Nutrition Examination Survey 1999-2010, approximately 30% of persons aged 60 years and above have untreated isolated systolic hypertension, as compared with 6% in adults aged 40 to 50 years and 1.8% in young adults aged 18 to 39 years[3][4][5]. As per the Framingham Heart Study, a person aged 65 years with normal blood pressure has a 90% lifetime risk of developing hypertension. Among the elderly group, women and non-Hispanic blacks have a higher prevalence of hypertensive disorders.


Isolated systolic hypertension, in most cases, develops as a result of the reduced elasticity of the arterial system. This is commonly seen among the elderly as there is increased deposition of calcium and collagen to the arterial wall[6]. Hence, this may result in reduced compliance of the arterial vessels, decreased lumen-to-wall ratio, and increased thickening and fibrotic remodeling of the vascular intima and media. As a result, these stiffened conduit arteries lead to the increase in pulse pressure and pulse wave velocity, causing an elevation in SBP and a further decline in DBP. Similarly, chronic diseases such as the above causes of secondary hypertension may contribute to the same pathological process by accelerating the deposition of calcium and collagen to the arterial system and the fibrotic remodeling of the vascular walls[6][7].

History and Physical

Isolated systolic hypertension, like any other hypertensive disorders, often results in end-organ damage when untreated. Hence, early diagnosis, addressing modifiable risk factors, and initiating appropriate treatment are prudent to decrease morbidity and mortality. The important aspects of the history in the hypertensive patient include the following[2][8]:

  • Intake of precipitating agents such nonsteroidal anti-inflammatory drugs, steroids, sympathomimetics, cocaine, steroids, estrogen
  • Risk factors such as smoking, diabetes, dyslipidemia, obesity, sedentary lifestyle, unhealthy diet
  • Diet, including high salt, processed food, high fat, and alcohol intake
  • Family history of hypertension, renal disease, diabetes, or cardiovascular disease
  • Symptoms of secondary causes such as spells of tremor, sweating or tachycardia, muscle weakness, thinning of the skin, depression, hematuria, loud snoring, and daytime somnolence
  • Symptoms of end-organ damage such as headaches, loss of visual acuity, dyspnea, chest pain, and claudication

Physical Examination

Accurate Blood Pressure Measurement

  • Reassess normal blood pressure yearly.
  • Take blood pressure after the patient rests for 5 minutes.
  • The patient should sit in a chair with both feet flat on the ground and the back straight.
  • The patient's arm should be placed on a flat surface at the level of the chest or heart.
  • Choosing the right cuff size is important. 
  • SBP is the first Korotkoff sound.
  • DBP is the fifth Korotkoff sound.
  • Obtain an average of 2 to 3 blood pressure measurements on 2 or 3 separate occasions to confirm a hypertension diagnosis.

General Appearance

  • Body mass index calculation
  • Signs of Cushing syndrome such as buffalo hump, moon face, thinning of the skin, and red or purple striae.
  • Restlessness
  • Sweating
  • Flushing
  • Neurofibromatosis


  • Thyroid enlargement
  • Carotid bruits


  • Papilledema
  • Cotton wool spots
  • Arteriolar narrowing 
  • Arteriovenous nicking
  • Hemorrhage


  • Gallop rhythm, S4 
  • Heave
  • Jugular venous distension


  • Rales
  • Rhonchi


  • Enlarged kidneys 
  • Aorta or renal bruits


  • Visual changes
  • Confusion
  • focal weakness


  • Peripheral pulses
  • Pedal edema
  • Cold peripheral limbs


Further Evaluation 

When systolic hypertension is suspected based on the reliable measurements, perform further evaluation to determine the following[2][8].

  • Presence or absence of cardiovascular risk factors
  • Extent of the end-organ damage
  • Identifiable causes of hypertension
  • Concomitant clinical conditions affecting prognosis and treatment

Routine Laboratory and Clinical Investigation 

These tests should be performed to evaluate cardiovascular risk and concomitant diseases.

  • 12-lead electrocardiographic (left ventricular hypertrophy features, atrial dilation, and arrhythmias)
  • Lipid panels (calculate 10-year atherosclerotic cardiovascular disease (ASCVD) risk)
  • Serum creatinine (with estimation of GFR)
  • Serum electrolytes (sodium and potassium)
  • Thyroid-stimulating hormone 
  • Urine analysis (proteinuria)
  • Urine microalbuminuria  

Additional Tests

Perform the following tests based on the relevant history, physical examination, and routine laboratory findings.

  • Hemoglobin A1c
  • Serum uric acid
  • Ankle-brachial index 
  • Renal ultrasound and renal duplex Doppler ultrasonography
  • Quantitative proteinuria (urine protein to creatinine ratio, 24-hour urine protein)
  • Echocardiogram (patient with heart failure)
  • Specific tests to search for secondary causes of hypertension (plasma free metanephrines, 24-hour urinary cortisol, aldosterone-renin ratio)  

Treatment / Management

New classifications of blood pressure according to the 2017 ACC/AHA guidelines[2]:

Normal Blood Pressure 

  • SBP < 120 mmHg and DBP < 80 mmHg
  • Promote lifestyle modification.

Elevated Blood Pressure

  • SBP 120 to 129 mmHg and DBP < 80 mmHg
  • Initiate nonpharmacologic therapy and reassess in three to six months.

Hypertension Stage 1

  • SBP 130 to 139 mmHg or DBP 80 to 89 mmHg
  • Patient without ASCVD or 10-year ASCVD risk < 10%: initiate nonpharmacologic therapy for all patients and reassess in three to six months.
  • Patient with ASCVD or 10-year ASCVD risk >/= 10%: initiate nonpharmacologic therapy and single oral antihypertensive agent and reassess patient in one month.

Hypertension Stage 2

  • : SBP > 139 mmHg or DBP > 89 mmHg
  • Initiate nonpharmacologic therapy and single oral antihypertensive agent and reassess patient in one month.

*If the blood pressure goal is not met, assess and optimize adherence to therapy or consider intensification of therapy.

*If the blood pressure goal is met, reassess in three to six months.

Several clinical trials such as HYpertension in the Very Elderly (HYVET) and Systolic Hypertension in the Elderly Program (SHEP) have shown that active treatment of isolated systolic hypertension in older adults resulted in significant reductions in the all-cause mortality (13%), cardiovascular mortality (18%), and stroke (30%) and coronary (23%) events as compared with placebo.

Treatment of hypertension can be divided into nonpharmacologic and pharmacologic therapy[2][8]

Nonpharmacologic Therapy

  • Recommended for all patients, regardless of the reading of the blood pressure.
  • Restrict dietary salt (aim for 1.5 g or less per day). Randomized controlled trials have shown that moderate sodium reduction can result in an average blood pressure reduction of 4.8/2.5 mmHg).
  • Weight loss (every 1 pound of weight loss will result in a reduction of 1 mmHg blood pressure). 
  • Start a Dietary Approaches to Stop Hypertension (DASH) diet (rich in fruits, vegetables, whole grains, fish, and low- fat dairy products). A clinical trial has shown that the DASH diet helps to reduce blood pressure by an average of 6/4 mmHg.
  • Increase physical activity. Aerobic and resistance training can reduce the blood pressure by an average of 4/3 to 6/3 mmHg, irrespective of the body weight.
  • Limit alcohol intake to no more than one alcoholic drink per day for women and two for men.
  • Take a potassium supplement (unless contraindicated in chronic kidney disease patient).
  • Quit smoking.
  • Use stress management.

Pharmacologic Therapy

  • In general, start off with a single agent oral antihypertensive drug therapy, especially in the elderly because of the risk of orthostatic hypotension.
  • An exception to the above is when the initial the SBP is above 160 or blood pressure is > 20/10 mmHg above the goal of blood pressure, which often needs the initiation of two oral antihypertensive agents.
  • The four major classes of oral antihypertensive agents include thiazide-like diuretics (chlorthalidone and indapamide), dihydropyridine calcium channel blockers (CCBs: amlodipine, nifedipine, nitrendipine), angiotensin-converting enzyme inhibitors (ACEi: lisinopril, ramipril), and angiotensin receptor blockers (ARBs: losartan, valsartan).  
  • Randomized controlled trials have shown that thiazide-like diuretics and CCBs are the preferred first-line agents in reducing the risk of stroke and other morbidities in patients with isolated systolic hypertension.
  • The dose of the single oral antihypertensive agent should be titrated to the maximum before initiating a second oral antihypertensive agent. 
  • In patients who require two oral antihypertensive agents, a combination of thiazide-like diuretic and CCB is the preferred strategy.
  • ACEi or ARB is often used in the patient with compelling indications such as heart failure reduced ejection, post-myocardial infarction, diabetes, or chronic kidney disease.
  • A combination of either ACEi or ARB with CCB or thiazide-like diuretic can be considered.
  • It is important to note that ACEi should never be used concomitantly with ARB under any circumstances. 
  • Patients with secondary causes of hypertension should have their respective diseases addressed concurrently.
  • Studies have shown that the use of beta-blockers in the management of hypertension is inferior compared with ARB, ACEi or CCB for cardiovascular and stroke risk reduction.  

Blood Pressure Goals

  • SHEP and HYVET trials have shown significant benefits of antihypertensive treatment in patients with the goal of SBP <150 mmHg[9].
  • The VALsartan in Elderly Isolated Systolic Hypertension (VALISH) trial showed no significant difference in the primary outcome of sudden death, fatal or nonfatal myocardial infarction and stroke, heart failure death, or other cardiovascular death among patients with strict (< 140 mmHg) and moderate (140 to 150 mmHg) SBP control[10].
  • However, the VALISH trial was underpowered due to the low number of events.
  • Hence, the optimal SBP in patients with hypertensive disorder remained a controversial topic.
  • The most recent Systolic Blood Pressure Intervention Trial (SPRINT) has shown that intensive SBP target of < 120 mmHg improved the cardiovascular outcomes and the overall survival compared to the standard SBP target of 135 to 139 mmHg[11].
  • However, aggressive SBP lowering may be harmful in the elderly and incite more adverse effects such as hypotension, end-organ hypoperfusion (causing acute kidney injury and intracranial hypoperfusion which may link to cognitive decline), and polypharmacy. 
  • It is suggested that a goal blood pressure of < 130/80 mmHg is appropriate as long as the patient tolerates it.
  • Otherwise, < 140/90 mmHg is considered reasonable in patients who are in the elderly population and patients with labile blood pressure or polypharmacy.
  • Management strategies should always be patient-centered, with the aim of optimizing blood pressure control and avoiding polypharmacy, especially in the elderly.

J-curve Phenomenon[12][13]

  • Various studies have shown a J-curve association between blood pressure with risk of myocardial infarction and death.
  • Patients with isolated systolic hypertension who receive antihypertensive treatment may precipitously drop their DBP as well.
  • As myocardial perfusion occurs mainly during diastole, an excessive drop in DBP may increase the risk of cardiovascular disease and death.

Differential Diagnosis

It is important to identify white coat hypertension and masked hypertension correctly as over- or under-treatment of hypertension can have significant morbidity and mortality.

White coat Hypertension

  • Consistently elevated office blood pressure but normal out-of-office blood pressure

Masked Hypertension

  • Consistently elevated out-of-office blood pressure but normal office blood pressure


  • Result of calcified blood vessels that cause incompressible of the peripheral arteries
  • Blood pressure cuff unable to measure the intraluminal blood pressure accurately
  • This causes a false elevation of blood pressure reading
  • Use of standing blood pressure measurement can help to differentiate pseudo-hypertension from true hypertension
  • Patients with poorly controlled blood pressure should be evaluated for pseudo-hypertension prior to being labeled as resistant hypertension.

Pearls and Other Issues

Isolated systolic hypertension is common in patients in the elderly population. SBP has a better prediction for risk of cardiovascular disease as compared to DBP. Hence, treatment of isolated systolic hypertension is beneficial to reduce all-cause mortality and cardiovascular risk and stroke. The optimal SBP remained unclear, but an SBP goal of < 140 mmHg and keeping DBP at 70 mmHg or higher are considered appropriate in most patient populations.  

Enhancing Healthcare Team Outcomes

Systolic hypertension is commonly encountered in clinical practice. Because it is a major risk factor for adverse cardiac events, the condition must be appropriately managed. The nurse practitioner, primary care provider, internist, cardiologist, and emergency department physician must be aware of the latest ACC guidelines on the management of hypertension. Because of the numerous drugs available to treat hypertension, a consult with a cardiologist is highly recommended if there is any doubt about the efficacy of the drug. There is ample evidence showing that when systolic hypertension is well treated, the patients have good outcomes with an interprofessional approach to care. [15][16][17](Level 1)

Article Details

Article Author

Jian Liang Tan

Article Editor:

Kshitij Thakur


11/23/2020 8:51:08 AM

PubMed Link:

Systolic Hypertension



Isolated Systolic Hypertension: An Update After SPRINT., Bavishi C,Goel S,Messerli FH,, The American journal of medicine, 2016 Dec     [PubMed PMID: 27639873]


Whelton PK,Carey RM,Aronow WS,Casey DE Jr,Collins KJ,Dennison Himmelfarb C,DePalma SM,Gidding S,Jamerson KA,Jones DW,MacLaughlin EJ,Muntner P,Ovbiagele B,Smith SC Jr,Spencer CC,Stafford RS,Taler SJ,Thomas RJ,Williams KA Sr,Williamson JD,Wright JT Jr, 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018 Oct 23;     [PubMed PMID: 30354654]


Viera AJ,Neutze DM, Diagnosis of secondary hypertension: an age-based approach. American family physician. 2010 Dec 15     [PubMed PMID: 21166367]


Egan BM,Li J,Hutchison FN,Ferdinand KC, Hypertension in the United States, 1999 to 2012: progress toward Healthy People 2020 goals. Circulation. 2014 Nov 4     [PubMed PMID: 25332288]


Liu X,Rodriguez CJ,Wang K, Prevalence and trends of isolated systolic hypertension among untreated adults in the United States. Journal of the American Society of Hypertension : JASH. 2015 Mar     [PubMed PMID: 25795550]


AlGhatrif M,Lakatta EG, The conundrum of arterial stiffness, elevated blood pressure, and aging. Current hypertension reports. 2015 Feb     [PubMed PMID: 25687599]


Chobanian AV, Clinical practice. Isolated systolic hypertension in the elderly. The New England journal of medicine. 2007 Aug 23     [PubMed PMID: 17715411]


Mancia G,Fagard R,Narkiewicz K,Redon J,Zanchetti A,Böhm M,Christiaens T,Cifkova R,De Backer G,Dominiczak A,Galderisi M,Grobbee DE,Jaarsma T,Kirchhof P,Kjeldsen SE,Laurent S,Manolis AJ,Nilsson PM,Ruilope LM,Schmieder RE,Sirnes PA,Sleight P,Viigimaa M,Waeber B,Zannad F, 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood pressure. 2014 Feb     [PubMed PMID: 24359485]


Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991 Jun 26     [PubMed PMID: 2046107]


Beckett NS,Peters R,Fletcher AE,Staessen JA,Liu L,Dumitrascu D,Stoyanovsky V,Antikainen RL,Nikitin Y,Anderson C,Belhani A,Forette F,Rajkumar C,Thijs L,Banya W,Bulpitt CJ, Treatment of hypertension in patients 80 years of age or older. The New England journal of medicine. 2008 May 1     [PubMed PMID: 18378519]


Wright JT Jr,Williamson JD,Whelton PK,Snyder JK,Sink KM,Rocco MV,Reboussin DM,Rahman M,Oparil S,Lewis CE,Kimmel PL,Johnson KC,Goff DC Jr,Fine LJ,Cutler JA,Cushman WC,Cheung AK,Ambrosius WT, A Randomized Trial of Intensive versus Standard Blood-Pressure Control. The New England journal of medicine. 2015 Nov 26     [PubMed PMID: 26551272]


Kimm H,Mok Y,Lee SJ,Lee S,Back JH,Jee SH, The J-curve between Diastolic Blood Pressure and Risk of All-cause and Cardiovascular Death. Korean circulation journal. 2018 Jan     [PubMed PMID: 29322696]


Kang YY,Wang JG, The J-Curve Phenomenon in Hypertension. Pulse (Basel, Switzerland). 2016 Jul     [PubMed PMID: 27493904]


Zweifler AJ,Shahab ST, Pseudohypertension: a new assessment. Journal of hypertension. 1993 Jan     [PubMed PMID: 8382233]


Benetos A,Petrovic M,Strandberg T, Hypertension Management in Older and Frail Older Patients. Circulation research. 2019 Mar 29;     [PubMed PMID: 30920928]


Ojji DB,Mayosi B,Francis V,Badri M,Cornelius V,Smythe W,Kramer N,Barasa F,Damasceno A,Dzudie A,Jones E,Mondo C,Ogah O,Ogola E,Sani MU,Shedul GL,Shedul G,Rayner B,Okpechi IG,Sliwa K,Poulter N, Comparison of Dual Therapies for Lowering Blood Pressure in Black Africans. The New England journal of medicine. 2019 Mar 18;     [PubMed PMID: 30883050]


Poblete F,Barticevic N,Bastías G,Quevedo D,Vargas I, [Effectiveness of a case management intervention for high blood pressure and type II diabetes in primary health care]. Revista medica de Chile. 2018 Nov;     [PubMed PMID: 30725040]